Luke Jones

This study investigates how PRC2 depletion in AML affects epigenomic and transcriptional changes, revealing altered chromatin accessibility, H3K27me3 levels, and gene expression patterns that impact cell phenotype and treatment response.

This paper uses a structure-based model to identify synergistic RAF inhibitor combinations effective against RAS-mutant AML in vitro and in vivo.

The paper generates hiPSC lines from patients with extreme polygenic scores for QT interval to study LQTS genetic and cellular complexity.